CURRICULUM VITAE
06/12/2009
BEATA C. CASANAS, DO
Infectious Disease Center
Tampa General Hospital
Tampa, Florida 33601
(813) 844-4187 Office
(813) 844-7605 Fax
Hillsborough County Health Department
Specialty Care Center
1105 E. Kennedy Blvd.
Tampa, FL 33602
PLACE OF BIRTH: Zawiercie, Poland
CITIZENSHIP: US
EDUCATION:
Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, 1999, DO
University of South Florida, Honors Program, Tampa, 1993, BS
POSTGRADUATE TRAINING:
Infectious Diseases Fellowship, University of South Florida, Tampa, 2003 – 2005.
Internal Medicine Residency, University of South Florida, Tampa, 2000 – 2003.
General Rotating Internship, Nova Southeastern University College of Osteopathic Medicine,
Fort Lauderdale, 1999 – 2000.
CERTIFICATIONS:
Diplomate, American Board of Internal Medicine, Infectious Diseases, 2005 – 2015. Number
218243.
Diplomate, American Board of Internal Medicine, 2003 – 2013.
Diplomate, National Board of Medical Examiners, 2000.
ACADEMIC APPOINTMENTS:
Advisor, Medical Health Administration, Employee/Student Health and Wellness, University
of South Florida, College of Medicine, Tampa, 2008 – present.
Faculty Mentor, Scholarly Concentrations in Research, University of South Florida, College
of Medicine, Tampa, 2008 – present.
CURRICULUM VITAE
Beata Casanas, DO
2
Faculty, Volunteer Preceptor for the University of South Florida College of Medicine
Longitudinal Clinical Experience (LCE) Program, Tampa, 2006 – present.
Faculty, Florida/Caribbean AIDS Education and Training Center, 2006 – present.
Faculty Mentor, Scholarly Concentrations in Public Health: Global Approaches to Clinics
and Communities, University of South Florida, College of Medicine, Tampa, 2006 – present.
Faculty Mentor, Scholarly Concentrations in Healthcare Disparities, University of South
Florida, College of Medicine, Tampa, 2006 – present.
Assistant Professor of Medicine, Division of Infectious Diseases, University of South Florida
College of Medicine, Tampa, 2005 – present.
Chief Fellow, Division of Infectious Disease and International Medicine Fellowship
Program, University of South Florida, Tampa, 2004 – 2005.
Associate Director, Lifelink Microbiology Laboratory, Florida, 2001 – present.
ADMINISTRATIVE POSITIONS:
Hillsborough County Health Department, Tampa, Florida
Executive Medical Director (2006 – Present): Provide medical supervision to medical staff of
the health department – pediatric physicians, OB/GYN nurse practitioners / midwives.
Review policies and appraise practitioners.
Medical Director of Tuberculosis Clinic (2005 – Present): Provide medical care to patients
with tuberculosis, supervise physician assistant and nursing staff providing care, act as a
resource for physicians and the community for tuberculosis related issues
Communicable Disease Director (2005 – 2006): Provide medical supervision, review
policies and appraise practitioners for disease control programs including HIV/AIDS, STDs,
Refugee Health, Immunizations and Epidemiology.
INTERNATIONAL AFFAIRS:
Faculty, Stephen Klasko Clinical Observership, Office of International Affairs and the
Division of Infectious Disease, in collaboration with Yeungnam University, South Korea,
2008 – present.
Faculty, International Health Service Collaborative (IHSC), La Sabana, Dominican Republic,
2006.
Faculty, American International Health Alliance, Curriculum Development, Almaty,
Kazakhstan, 2006.
Faculty, CHART-India (Center for Health, HIV/AIDS Research and Training in India)
Scholars Program, College of Public Health, Division of Infectious Diseases, University of
South Florida, Tampa, Florida, 2001 – present.
LABORATORY EXPERIENCE:
Microbiology Quality Assurance Manager, Lifelink Tissue Bank, Tampa, 2000 – present.
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
3
Research Assistant, Immunology, University of South Florida, Tampa, 1992 – 1993.
Laboratory Assistant, Microbiology, University of South Florida, Tampa,
1990 – 1993.
HONORS AND AWARDS:
Co-Valedictorian, 13th Class of the Public Health Leadership Institute of Florida, Tampa,
2008 – 2009.
Award in Appreciation of Outstanding Contribution to the Miami-Dade County Health
Department’s Tuberculosis Program, Miami, 2009.
Certificate of Appreciation in Recognition of Performance, Service and Dedication to Our
Children, Florida Department of Juvenile Justice, Office of Health Services, Orlando, 2009.
Silver Performance Award For Outstanding Contributions 2006/2007, University of South
Florida, College of Medicine, Department of Internal Medicine, Tampa, 2007.
Outstanding Infectious Disease Fellow, James A. Haley Veterans Hospital, Tampa, 2005.
Alpha Omega Alpha, Gamma Chapter, University of South Florida, Tampa, 2002.
Jeopardy winner (Four times), James A. Haley VA Hospital, Tampa, 2000 – 2002.
Resident of the Month Award, James A. Haley VA Hospital, Tampa, 2001, 2002.
Infectious Diseases Award, The Indian Practitioner Group, Mumbai, India, 2001.
The 1st Dr. Peter Mamunes Award - Best Pediatric Medical Student, Broward General
Medical Center, Ft. Lauderdale, 1998.
Chancellor’s List, Nova Southeastern University College of Medicine, Ft. Lauderdale,
1997.
Southern Medical Association Scholarship, Nova Southeastern University, Ft. Lauderdale,
1997.
Dean’s List, Nova Southeastern University College of Medicine, Ft. Lauderdale, 1996.
Golden Key National Honor Society, University of South Florida, Tampa, 1990.
FELLOWS TRAINED:
2008: Sally Alrabaa, MD; Aliyah Baluch, MD; Fariba Donovan, MD; Dhanashree Kelkar,
MD; Marela Velez, MD
2007: Michelle Mizrachi, MD; Theingi Oo, MD; Tri Pham, MD
2006: Daniela Chiriboga, MD; Yagneshvari Patel, DO; Chakrapol Sriaroon, MD
2005: Juan Diaz, DO; Anibal Maldonado, MD; Abbigail Chandler, MD; Javier Marinez,
MD
TEACHING ACTIVITIES:
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
4
Tuberculosis
PHC 6510
Scholarly Concentration in International Medicine, 2009.
Tuberculosis, 2008
BMS 6300
HIV, Tuberculosis, 2008.
Faculty Mentor
Faculty Mentor
Faculty Mentor
BMS 6920
Scholarly Concentrations in Research, 2008.
Scholarly Concentration in Public Health: Global Approaches to Clinics
and Communities, 2006 – Present.
Scholarly Concentrations in Healthcare Disparities, 2006 – Present.
Colloquium I/II, College of Medicine, Lecturer, 2006 – Present.
BCC 6110
Internal Medicine Clerkship, Attending, 2005 – Present.
MEL 9999
Independent Study in Infectious Diseases, Attending, 2005 – Present.
MEL 8371
Selected Topics in Infectious Disease, 2005 – Present.
MEL 7310
Infectious Diseases Clinical Elective, 2005 – Present.
Faculty
Longitudinal Clinical Experience (LCE), 2005 – Present.
GRADUATE MEDICAL EDUCATION:
Invited Guest Speaker, World TB Day 2009 Conference: I am Stopping TB, Miami-Dade
County Health Department Tuberculosis Control and Prevention Program, Miami, 2009.
Invited Guest Speaker, 5-Day STD Intensive Course, Southeast STD/HIV Prevention
Training Center, Miami-Dade Health Department, Miami, 2009.
Invited Guest Speaker, Pathogenesis and Treatment of Lipodystrophy in HIV, 18th Annual
HIV Conference of the Florida / Caribbean AIDS Education and Training Center, Orlando,
2009.
Invited Guest Speaker Webinar, Global Trends in TB: Live Meeting Dr. Beata Casanas,
Tampa, 2009.
Invited Guest Speaker, TB and HIV: Double Trouble, 2009 Department of Juvenile Justice,
Office of Health Services, Annual Training in Orlando, 2009.
Invited Guest Speaker, Hepatitis, Southeast STD/HIV Prevention Training Center,
Hillsborough County Health Department, Tampa, 2009.
Invited Guest Speaker, Update in Tuberculosis, First Annual Infectious Disease in
Correctional Facilities Summit, Orlando, 2008.
Invited Guest Speaker, Pediatric Environmental Health and Medicine, Pediatric Ground
Rounds, Department of Pediatrics, University of South Florida, Tampa, 2008.Invited Guest
Speaker, Update in Infectious Diseases, Geriatrics Annual Conference, Orlando, 2008.
Invited Guest Speaker, Tuberculosis, Annual Tuberculosis Statewide Meeting, Orlando,
2008.
Invited Guest Speaker, Sexually Transmitted Hepatitis, Southeast STD/HIV Prevention
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
5
Training Center, Hillsborough County Health Department, Tampa, 2008.
Invited Guest Speaker, Emergencies in Infectious Diseases. Internal Medicine, University of
South Florida, Tampa, 2008.
Invited Guest Speaker, Tuberculosis and HIV, Grand Rounds, Department of Internal
Medicine, University of South Florida, Tampa, 2008.
Invited Guest Speaker, Viral Hepatitis, Southeast STD/HIV Prevention Training Center,
Hillsborough County Health Department, Tampa, 2008.
Invited Guest Speaker, Syphilis, Southeast STD/HIV Prevention Training Center,
Hillsborough County Health Department, Tampa, 2008.
Invited Guest Speaker, HIV/AIDS Update, Grand Rounds, Department of Ophthalmology,
University of South Florida, Tampa, 2007.
Invited Guest Speaker, Tuberculosis and HIV Interactions, Annual Tuberculosis Statewide
Meeting, Tampa, 2007.
Invited Guest Speaker, Tuberculosis 101, Annual Tuberculosis Statewide Meeting, Tampa,
2007.
Invited Guest Speaker, Sexually Transmitted Hepatitis, Southeast STD/HIV Prevention
Training Center, Hillsborough County Health Department, Tampa, 2007.
Invited Guest Speaker, Environmental Medicine, Pediatric Grand Rounds, Department of
Pediatrics, University of South Florida, Tampa, 2007.
Invited Guest Speaker, Tuberculosis and HIV, Infectious Disease Fellows Introductory
Lecture Series, University of South Florida, Tampa, 2007.
Invited Guest Speaker, Emergencies in Infectious Diseases, Department of Internal
Medicine, University of South Florida, Tampa, 2007.
Invited Guest Speaker, Sexually Transmitted Diseases, Department of Internal Medicine,
University of South Florida, Tampa, 2007.
Invited Guest Speaker, Immunizations in End Stage Renal Disease Patients, National Kidney
Foundation’s 4th Annual Renal Professionals Forum, Port Canaveral, 2007.
Invited Guest Speaker, Tuberculosis Infection, Medical Student Infectious Disease
Colloquium, College of Medicine, University of South Florida, Tampa, 2006.
Invited Guest Speaker, Tuberculosis and HIV Coinfection, Combined Medical Directors and
Public Health Nursing Leaders Conference, Orlando, 2006.
Invited Guest Speaker, Avian Influenza, Hillsborough County Bar Health Law Section,
Tampa, 2006.
Invited Guest Speaker, New Advances in HIV Treatment, Grand Rounds, Orlando Regional
Medical Center, Orlando, 2006.
Invited Guest Speaker, Tuberculosis and HIV Interactions, Department of Internal Medicine,
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
6
University of South Florida, Tampa, 2006.
Invited Guest Speaker, Testing of Potential Tissue Donors, Lifelink Tissue Bank, Tampa,
2006.
Invited Guest Speaker, Public Health and Medicine, Regional Medical Education Partnership
Meeting On Curriculum Development, Almaty, Kazakhstan, 2006.
Invited Guest Speaker, Clinical Update on HIV/AIDS, Grand Rounds, Regional Medical
Education Partnership Meeting On Curriculum Development, Almaty, Kazakhstan, 2006.
Invited Guest Speaker, HIV/AIDS Update, Grand Rounds, Department of Ophthalmology,
University of South Florida, Tampa, 2005.
Invited Guest Speaker, Nosocomial Infections, College of Public Health, University of South
Florida, Tampa, 2004.
Invited Guest Speaker, Clinical Use of Antibiotics, College of Medicine, University of South
Florida, Tampa, 2004.
Invited Guest Speaker, History of HIV, College of Public Health, University of South
Florida, Tampa, 2003.
EDITORIAL POSITIONS:
Peer Reviewer, AIDS Care, 2009.Peer Reviewer, Infections in Medicine, 2007 – present.
Relevance Reviewer, Infectious Disease, American Board of Internal Medicine, 2006 –
present.
COMMITTEES:
Governmental Relations Committee, University of South Florida, Tampa, 2008 – 2011.
Faculty Senate, College of Medicine, University of South Florida, Tampa, 2008 – 2011.
Vice President, Florida Society of Preventive Medicine, Tampa, 2008-2009.
Secretary Treasurer, Florida Society of Preventive Medicine, Tampa, 2007 – 2008.
Member, Medical Subcommittee, Health Care Advisory Board, Tampa, 2007 –present.
Invited Testimony: Florida House of Representatives: Human Papilloma Virus Vaccine Bill
Testimony, Tallahassee, 2007.
TEXTBOOKS AND CHAPTERS:
1. Sinnott JT, Casanas B, Cooks A, Cooper C, et al. Abdominal Infections. In: MacCue J,
Kahan S eds. In A Page Infectious Disease. Baltimore: Lippincott Williams & Wilkins,
2007.
PUBLICATIONS:
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
7
1. Keeler J, Casanas BC, Murphy M. Duration of Tuberculosis Treatment in Patients with
HIV – pending submission.
2. Velez M, Casanas BC, Greene JN. Pasteurella multocida Infections in Cancer Patients
– pending submission.
3. Ramarao S, Casanas BC, Greene JN. Cutaneous Tuberculosis – pending submission.
4. Casanas BC, Carpenter E, Logan J. Tradition Meets Modern Medicine – pending
submission.
5. Datta I, Casanas BC, Vincent AL, Greene JN. The Red Face: Erysipelas versus
Parvovirus B19, SLE and Rosacea – submitted, Infections in Medicine.
6. Casanas BC, Pothiawala S, Sinnott JT. An Elderly Man with NOMA Orofacial
Gangrene. Infectious Diseases in Clinical Practice; 17(3);208-209, May 2009.
7. Casanas BC, Maldonado A, Diaz J, Logan J. Mycobacterium leprosum. Infections in
Medicine; 25:11, 526-527, 2008.
8. Gompf SG, Herman BC, Tash K, Sinnott JT. A Dim View: Corneal Ulcer after Remote
Refractive Surgery, Infections in Medicine; 22:621, 2005.
9. Gompf SG, Herman BC, Tash K. Pseudomonas aeruginosa corneal ulcer. Clin Micro
Newsletter, Volume 27, Issue 8, 15:64-65, April 2005.
10. Montero JA, Bartels LJ, Herman BC, Sinnott JT. Tuberculous otitis. Infections in
Medicine; 19:72, 2002.
11. Herman BC. Mycobacterium paratuberculosis: A role in Crohn’s disease? The Indian
Practitioner; 54:3, 2001.
12. Herman BC. One source or two source tradition? University of South Florida, Honors
Thesis, 1993.
ELECTRONIC ARTICLES:
1. Gompf SG, Casanas B. Herpangina. eMedicine Journal [serial online]. 2008. Available at:
http://www.emedicine.com/med/topic1004.htm
2. Casanas BC. Tuberculosis – Are You at Risk? April 26, 2007. Found at:
http://abcnews.go.com/Health/Germs/story?id=3079114&page=1.
3. Casanas BC. Tuberculosis - What You Need to Know. May 30, 2007. Found at:
http://abcnews.go.com/Health/Germs/story?id=3226324&page=1.
INSTRUCTIONAL TOOLS:
1. Casanas BC, Logan J. Development of new clinical rotation: Scholarly Concentration
Student Rotation with Disease Control at Hillsborough County Health Department, 2009.
2. Casanas BC, Diaz J. HIV/AIDS Learning Module for Primary Care Physicians, Regional
Medical Educational Partnership Meeting on Curriculum Development, American
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
8
International Health Alliance, Almaty, Kazakhstan, 2006.
ABSTRACTS:
1. Velez M, Casanas B, Greene J, Sandin R. Pasteurella multocida Infections in Cancer
Patients. 47th Annual Meeting Infectious Disease Society of America, Philadelphia, 2009.
– submitted.
2. Frank R, Casanas B. Meningitis and fungemia caused by amphotericin B resistant
Cryptococcus neoformans, Focus on Fungal Infections 19, Sanibel Harbour, 2009.
3. Casanas B, Benemon C, Lewis J, Olwe B, Russ D, Samuel-Wyatte D, Zamore B. These
are the factors of our TB. Hillsborough County Health Department. Bureau of TB and
Refugee Health Statewide Meeting: As The World Turns With TB And Refugee Health,
Orlando, 2008.
4. Casanas BC, Wallach P, DeBaldo A, Conaboy K, Bognar B, Charles P, Orriola J,
Nugmanova Z, Yegeubaeva S, Fedullo E. Developing Faculty Curriculum Skills while
Addressing Population Health Needs, AMEE, Genoa, Italy, 2006.
5. Gompf SG, Herman BC, Tash K, Grafals M. Corneal Ulcer: A Glimpse of Complexity,
Associates Meeting, American College of Physicians, Jacksonville, 2004.
PROFESSIONAL ORGANIZATIONS:
Florida Public Health Association, 2008 – present.
Florida Society of Preventive Medicine, 2007 – present.
Hillsborough County Medical Association, 2007 – present.
Florida Medical Association, 2007 – present.
Infectious Disease Society of America, 2004 – present.
American Medical Association, 2000 – present.
American College of Physicians – American Society of Internal Medicine, 2000 – present.
American Osteopathic Association, 1995 – present.
COMMUNITY OUTREACH:
Multimedia Press Conference, Tuberculosis Case in High School, Bay News 9, et al., Tampa,
2009.
Invited Guest Speaker, Career in Medicine, Undergraduate Pre-Medical Society, University
of South Florida, Tampa, 2009.
Invited Guest Speaker, Update in HIV/AIDS, Annual World AIDS Day Program,
Hillsborough County Health Department, Tampa, Florida, 2008.
Invited Guest Speaker, Influenza, Brandon Regional Hospital, Brandon, 2008.
Faculty Mentor & Volunteer, BRIDGE Healthcare Clinic, Student-Run Free Clinic, 2007 –
present.
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
9
Project Coordinator, World AIDS Day Health Fair Community Event, Tampa, 2007.
Media Interview, Tuberculosis Update, WFLA 970AM, Tampa, 2007.
Volunteer Physician, Free Back to School Physicals and Immunizations, University Area
Community Health Center, Tampa, 2007.
Media Interview, World Tuberculosis Day, WQYK 99.5FM, Interview with Rita Cicciello,
Tampa, 2007.
Media Interview, Flu Makes an Early Showing Across State, St. Petersburg Times, Tampa,
2006.Media Interview, Tuberculosis, Fox Channel 13, Tampa, 2006.
Media Interview, Highlights of the Bureau of Tuberculosis and Refugee Health Statewide
Meeting, Channel 8, Tampa, 2006.
Media Interview, Tuberculosis Outbreak, Channel 8, Tampa, 2006.
Invited Guest Speaker, Hepatitis C, Tampa Bay Hepatitis Liver Disease Support Group,
Tampa, 2005.
GRANTS:
AETC – Aids Education and Training Center. (50% allocation). 2008 -2009. Funded $400,000.
SEPTC - Southeast Region STD/HIV Prevention Training Center. (30% allocation). 2008-2009.
Funded $151,400.
RESEARCH EXPERIENCE:
Principal Investigator Initiated Studies
Recurrent Tuberculosis: A new look at treating an old enemy. Role: PI
5/2009 – Present
The purpose of this research is to (1) Study the recurrence rate of Tuberculosis in HIV negative
and HIV positive patients (2) Look at this patient population and determine if a difference exists
between the recurrence rates and lengths of treatment (3) Compare this to current CDC
recommended treatment regimen lengths for HIV positive and negative patients.
Ongoing Studies: Principal Investigator
Tibotec (TMC278-TiDP6-C209)
Role: PI
2/2008 – Present
A Phase III, randomized, double-blind trial of TMC278 75mg qd versus efavirenz 600 mg
q.d in combination with fixed dose background regimen consisting of tenofovir disoproxil
fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects
Napo Pharmaceuticals (NP303-101 ADVENT) Role: PI
6/2007 – Present
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess
the Efficacy and Safety of Crofelemer 125mg, 250 mg, and 500 mg Orally Twice Daily for
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
10
the Treatment of HIV-Associated Diarrhea (ADVENT Trial)
Tibotec (TMC278-204)
Role: PI
5/2006 – Present
A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in
Antiretroviral Naïve HIV-1 Infected Subjects.
Ongoing Studies: Co-Investigator
NIH (START)
Role: Co-Investigator
Strategic Timing of AntiRetroviral Treatment.
5/2009 – Present
Schering-Plough (P04875)
Role: Co-Investigator
4/2009 - Present
Efficacy and Safety of VICRIVIROC in HIV Infected Treatment-Naïve Subjects.
Pfizer (A4001078)
Role: Co-Investigator
03/2009 - Present
Pilot Study of Novel Combination of Maraviroc + Atazanavir/Ritonavir vs.
Atazanavir/Ritonavir + Emtricitabine/Tenofovir for the Treatment of Treatment Naïve HIVInfected Patients with R5 HIV-1.
Gilead (GS-US-164-0216)
Role: Co-Investigator
3/2009 - Present
The SWIFT Study: A Prospective, Randomized, Open-Label Phase IV Study to Evaluate the
Rationale of Switching from Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed-Dose
Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically-Suppressed, HIV-1 Infected
Patients Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral
Regimen.
Merck (IISP 33107)
Role: Co-Investigator
10/2008 – Present
A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir
versus NRTIs as a Backbone in HIV-Infected Patients Switched from a Stable Boosted PI
Regimen.
Schering Plough (P04889)
Role: Co-Investigator
6/2007 – Present
Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected
Treatment-Experienced Subjects (VICTOR-E4)
Gilead(GS-US-183-0130)
Role: Co-Investigator
05/2007 - Present
A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of
HIV-1 Infected Subjects.
Pfizer (A4001027)
Role: Co-Investigator
10/2004 – Present
A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5
antagonist, UK-427, 857, in combination with optimized background therapy versus
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
11
optimized background therapy alone for the treatment of antiretroviral-experienced HIV-1
Infected Subjects.
Closed/Completed Studies: Principal Investigator
Abbott Laboratories (M06-802)
Role: PI
12/2006 – 1/2008
A Phase 3, randomized, open-label study of lopinavir/ritonavir tablets 800/200 mg Oncedaily versus 400/100 mg twice-daily when coadministered with nucleoside/nucleotide
reverse transcriptase inhibitors in antiretroviral-experienced, HIV-1 infected subjects.
Tibotec (TMC125-C229)
Role: PI
5/2006 – 9/2008
An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who were Randomized to a
TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least
48 Weeks.
GlaxoSmithKline (COL100758)
Role: PI
5/2006 – 4/2008
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of
GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination.
Boehringer Ingelheim (BIPI 1182.12)
Role: PI
5/2006–9/2006
Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with
low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir
(PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST 1: Randomized
Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir).
Incyte (RVT 901)
Role: PI
5/2006 – 8/2006
A Long-Term, Open Label, Non-Randomized Study to Evaluate the Safety of 100 and 200
mg Reverset (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When
Used in Combination with Other Antiretroviral Agents.
GlaxoSmithKline (EPZ104057)
Role: PI
5/2006 –6/2008
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and
Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in
Antiretroviral-Naive HIV-1 Infected Subjects.
Closed/Completed Studies: Co-Investigator
Tibotec (TMC114-TiDP31-C229)
Role: Co-Investigator
11/2007 – 10/2008
A randomized open-label trial to compare the efficacy, safety and tolerability of DRV/rtv
(800/100 mg) qd versus DRV/rtv (600/100 mg) bid in early treatment-experienced HIV-1
infected subjects
Merck & Co, Inc (MK0518-032)
Role: Co-Investigator
3/2007 – 7/2008
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to evaluate the Safety
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
12
and Antiretroviral Activity of MK-0518 Versus KALETRA in HIV-Infected Patients
Switched from a Stable KALETRA Based Regimen – Study A
GlaxoSmithKline (EPZ108859)
Role: Co-Investigator
2/2007 – 2/2008
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the
Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by
Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose Combination Tablet
or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naïve
HIV-1 Infected HLA-B*5701 Negative Subjects.
NeurogesX, Inc. (C119)
Role: Co-Investigator
10/2006 – 5/2008
A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment
of Painful HIV-Associated Neuropathy.
Merck & Co, Inc (V520-011)
Role: Co-Investigator
8/2006 – 2/2008
A Study of the Safety, Tolerability, and Immunogenicity of HIV-1 gag DNA Formulated
With CRL1005 Adjuvant Followed by the Adenovirus Serotype 5 HIV-1 gag Vaccine (Ad5
HIV-1 gag) in a Prime/Boost Regimen.
Tibotec Pharmaceuticals (TMC125-C217)Role: Co-Investigator
7/2006 – 11/2008
An open-label trial with TMC125 as part of an ART including TMC114/RTV and an
investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial
(TMC125-C206 or TMC125-C216).
Gilead Sciences (GS-US-183-0105)
Role: Co-Investigator
5/2006 – 10/2007
A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced,
HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a
Comparator Ritonavir- Boosted Protease Inhibitor (CPI/r) in Combination with a Background
Antiretroviral Therapy.
Achillion Pharmaceuticals (ACH443-015)Role: Co-Investigator
5/2006 – 4/2007
A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination
with Efavirenz and Tenofovir versus Lamivudine in Combination with Efavirenz and
Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects, with a 12-Week Extension
Treatment Period.
Boehringer Ingelheim (BIPI 1182.12) Role: Co-Investigator
3/2006 – 5/2006
Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with
low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir
(PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST 1: Randomized
Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir).
GlaxoSmithKline (EPZ104057)
Role: Co-Investigator
3/2006 – 5/2006
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
13
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and
Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in
Antiretroviral-Naive HIV-1 Infected Subjects.
GlaxoSmithKline (COL100758)
Role: Co-Investigator
3/2006 – 5/2006
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of
GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination.
Tibotec (TMC278-204)
Role: Co-Investigator
3/2006 – 5/2006
A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in
Antiretroviral Naïve HIV-1 Infected Subjects.
Tibotec Pharmaceuticals (TMC125-C206) Role: Co-Investigator
1/2006 – 9/2008
A Phase III randomized, double-blind, placebo-controlled trial to investigate the efficacy,
tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an
investigator-selected OBR regimen in HIV-1 infected patients with limited to no treatment
options.
Tibotec Pharmaceuticals (TMC114-C211) Role: Co-Investigator
12/2005 – 5/2009
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of
TMC114/ritonavir versus lopinavir/ritonavir in treatment-Naïve HIV-1 infected subjects.
This trial will also be referred to as ARTEMIS.
Bristol Myers-Squibb (AI424128)
Role: Co-Investigator
8/2005 – 4/2006
A Phase IV, Multi-center, Cross-Sectional Study to Evaluate the I50L Substitution among
Subjects Experiencing Virologic Failure on a HAART regimen containing Atazanavir (ATV)
A Long-Term, Open Label, Non-Randomized Study to Evaluate the Safety of 100 and 200
mg Reverset (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When
Used in Combination with Other Antiretroviral Agents.
Tibotec (TMC125-C229)
Role: Co-Investigator
7/2005 – 5/2006
An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who were Randomized to a
TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least
48 Weeks.
Boehringer Ingelheim. (BI 1182.17)
Role: Co-Investigator
6/2005 – 1/2006
A Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of
Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects.
Tibotec (TMC114-C214)
Role: Co-Investigator
5/2005 – 3/2008
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of
TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
14
Tibotec (TMC 125-C211)
Role: Co-Investigator
3/2005 – 3/2006
An Open-Label Trial of TMC125 in HIV-1 Infected Subjects Who Were Randomized to an
Active Control Arm of Any Sponsor-Selected TMC125 Trial and Either Virologically Failed
or Completed the Entire Treatment Period.
Incyte (RVT 901)
Role: Co-Investigator
Bristol-Myers Squibb
Role: Co-Investigator
Resistance Testing of HIV-Positive Patients Entering Therapy.
2/2005 – 5/2006
12/2004 – 12/2005
GlaxoSmithKline (ESS100732) Role: Co-Investigator
8/2004 – 2/2006
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of
GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir
(400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine
(600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naïve HIV-1
Infected Adults Over 48 Weeks
Tibotec. (TMC125-C223)
Role: Co-Investigator
8/2004 – 6/2006
Incyte (INCB 8721 RVT-203) Role: Co-Investigator
6/2004 – 4/2006
A placebo-controlled, double-blind, parallel dose group study exploring the safety,
tolerability, and virological effect of 50, 100, and 200mg Reverset™ (RVT) in HIV-infected
antiretroviral therapy-experienced subjects when used in combination with other
antiretroviral agents.
Hoffman La-Roche
Role: Co-Investigator
1/2004 – 11/2005
Observational Cohort Study of Pneumonia in Fuzeon-Exposed and Non-Exposed Patients.
Boehringer Ingelheim. (BI 1182.58)
Role: Co-Investigator
10/2003 – 6/2006
An Open Label Study to Evaluate the Safety of Tipranavir plus Ritonavir When Used in
Combination with Other Agents for the Treatment of Patients with HIV Infection Who Have
Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited
Treatment Options.
Pfizer (A4311022)
Role: Co-Investigator
8/2003 – 12/2005
A Rollover Study for Subjects Continuing Treatment with Open-Label Capravirine Who
Were Enrolled in Study A4311006
Pfizer (A4311025)
Role: Co-Investigator
8/2003 – 12/2005
A Rollover Study for Subjects on Capravirine Who Wish to Continue Treatment with OpenLabel Capravirine fter Completing Study A4311002
A Randomized, controlled, partially blinded phase IIb dose-finding trial of TMC 125, in
HIV-1 infected subjects with documented genotypic evidence of resistance to currently
available NNRTIs and with at least three primary PI mutations.
3/9/2016
CURRICULUM VITAE
Beata Casanas, DO
15
Nonsponsored
Role: Co-Investigator
7/2003 – 6/2006
Collection and Preservation of Blood and Blood Component Specimens from HIV Infected
Patients for Collaborative Studies.
GlaxoSmithKline (APV 30005) Role: Co-Investigator
7/2003 – 3/2006
An Open-Label, Phase III Study to Assess the Long Term Safety Profile of GW433908
Containing Regimens in HIV-1 Infected Subjects.
Pfizer/Agouron (A4311006)
Role: Co-Investigator
7/2003 – 12/2005
A Phase 2, Randomized, Double-Blind, Dose-Ranging Study of Capravirine (AG1549) in
Combination with Kaletra and at least 2 Nucleoside Reverse Transcriptase Inhibitors in HIVinfected Subjects Who Have Failed Antiretroviral Regimens Containing Protease Inhibitors,
Nonnucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase
Inhibitors.
NIAID/NIH/DHHS
Role: Co-Investigator
7/2003 – 3/2008
A large simple trial comparing two strategies for management of anti-retroviral therapy (the
SMART Study) CPCRA.
Merck. (MRK 014)
Role: Co-Investigator
5/2002 – 6/2008
A probe study to evaluate the safety, tolerability, and immunogenicity of the MRK
adenovirus serotype 5 vector (MRKAd5) human immunodeficiency virus type 1 (HIV-1) gag
vaccine in HIV-1 infected individuals.
LANGUAGES:
Polish, English, Russian, Czech, and German
PERSONAL:
International competitions in professional horse jumping
Piano
Latin and Classical Dancing
3/9/2016